Michael Halstead Intra Cellular Therapies, Inc. (ITCI) insider trading activity

Michael Halstead is President of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 21,307 shares of ITCI, which is worth approximately $2.8 Million. The most recent transaction as insider was on Mar 10, 2025, when has been sold 3,757 shares (Common Stock) at a price of $131.24 per share, resulting in proceeds of $493,068. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.3K

Infinity% 3M change

Infinity% 12M change

Total Value Held $2.8 Million

Michael Halstead Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 10 2025	SELL Payment of exercise price or tax liability	$493,068 $131.24 p/Share	3,757 Reduced 14.99%	21,307 Common Stock
Mar 10 2025	BUY Exercise of conversion of derivative security	-	7,345 Added 22.66%	25,064 Common Stock
Mar 06 2025	SELL Payment of exercise price or tax liability	$881,334 $131.19 p/Share	6,718 Reduced 27.49%	17,719 Common Stock
Mar 06 2025	BUY Exercise of conversion of derivative security	-	13,133 Added 34.96%	24,437 Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$802,660 $128.2 p/Share	6,261 Reduced 35.64%	11,304 Common Stock
Mar 01 2025	BUY Exercise of conversion of derivative security	-	12,239 Added 41.06%	17,565 Common Stock
Jan 31 2025	SELL Payment of exercise price or tax liability	$722,757 $127.0 p/Share	5,691 Reduced 51.66%	5,326 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	11,017 Added 50.0%	11,017 Common Stock
Nov 13 2024	SELL Open market or private sale	$1,656,937 $88.54 p/Share	18,714 Reduced 100.0%	0 Common Stock
Nov 13 2024	BUY Exercise of conversion of derivative security	$690,359 $36.89 p/Share	18,714 Added 50.0%	18,714 Common Stock
Nov 12 2024	SELL Open market or private sale	$2,052,492 $89.75 p/Share	22,869 Reduced 100.0%	0 Common Stock
Nov 12 2024	BUY Exercise of conversion of derivative security	$547,483 $23.94 p/Share	22,869 Added 50.0%	22,869 Common Stock
Mar 11 2024	SELL Open market or private sale	$486,679 $66.26 p/Share	7,345 Reduced 100.0%	0 Common Stock
Mar 10 2024	BUY Exercise of conversion of derivative security	-	7,345 Added 50.0%	7,345 Common Stock
Mar 07 2024	SELL Open market or private sale	$872,884 $66.47 p/Share	13,132 Reduced 100.0%	0 Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	-	13,132 Added 50.0%	13,132 Common Stock
Feb 26 2024	SELL Open market or private sale	$548,745 $69.4 p/Share	7,907 Reduced 100.0%	0 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	-	7,907 Added 50.0%	7,907 Common Stock
Feb 02 2024	SELL Open market or private sale	$791,892 $66.77 p/Share	11,860 Reduced 100.0%	0 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	11,860 Added 50.0%	11,860 Common Stock
Jan 11 2024	SELL Open market or private sale	$3,353,499 $67.07 p/Share	50,000 Reduced 100.0%	0 Common Stock
Jan 11 2024	BUY Exercise of conversion of derivative security	$917,000 $18.34 p/Share	50,000 Added 50.0%	50,000 Common Stock
Nov 13 2023	SELL Open market or private sale	$2,684,500 $53.69 p/Share	50,000 Reduced 100.0%	0 Common Stock
Nov 13 2023	BUY Exercise of conversion of derivative security	$705,000 $14.1 p/Share	50,000 Added 50.0%	50,000 Common Stock
Mar 13 2023	SELL Open market or private sale	$327,322 $44.57 p/Share	7,344 Reduced 100.0%	0 Common Stock

Michael Halstead

President

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Value

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

Operation

Value

Type

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI

Account